Endomedix, Inc.

Endomedix, Inc. is a biotechnology and medical device company based in Montclair, New Jersey, founded in July 2014. The company focuses on developing innovative medical solutions using its patented precision polysaccharide chemistry platform. This technology allows for the creation of dynamic, structured medical devices during surgery, offering unique biomaterials with specialized mechanisms of action. The flagship product, PlexiClot™ Absorbable Hemostat, is designed to control bleeding in brain and spinal surgeries. It addresses a significant challenge in neurosurgery, targeting a $1.9 billion market. PlexiClot has demonstrated its effectiveness in large animal trials and is on track for FDA approval as the first device specifically for brain surgery. The company aims to reduce hospital costs associated with complications, including re-operations and extended hospital stays. Endomedix is led by a team with extensive experience in medical technology and regulatory affairs, supported by a network of physician investors. The company is currently in the prototype-ready stage, preparing for production scale-up and regulatory pathways.